Erbe introduces FiAPC® plus: Advancing control in flexible argon plasma coagulation
14.7.2025 13:00:00 CEST | Business Wire | Press Release
Erbe Elektromedizin GmbH presents its latest innovation in electrosurgery: the FiAPC® plus probes. They are designed for use in gastrointestinal and pulmonary endoscopy. Building upon decades of experience with argon plasma coagulation (APC), FiAPC® plus probes introduce advancements aimed at enhancing control, workflow efficiency, and procedural reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714417615/en/
Various versions of the FiAPC® plus probes with axial, lateral and circumferential openings available.
Designed to put control in the physician’s hands
With the FiAPC® plus probes, Erbe seeks to give physicians greater control over every aspect of the APC application: from energy delivery and beam formation to tip positioning and suction. "Precision in APC begins with control. And that’s exactly what FiAPC® plus is built to provide," Mariuccia Zambelli, Vice President Global Marketing, stated.
The new probes feature a thermally insulated tip, developed to minimize heat generation at the distal end of the instrument. This reduces tissue sticking and allows for a homogenous and consistent plasma beam, even in complex anatomies.
Versatility for GI and pulmonary applications
The FiAPC® plus probes are available in various versions with axial, lateral and circumferential openings for the plasma beam, offering physicians options that align with a wide range of clinical applications. The probes are compatible with Erbe’s full range of renowned APC modes - preciseAPC®, pulsedAPC® (slow and fast), and forcedAPC® - which can be selected to choose the right tissue effect for the corresponding tissue characteristics.
The FiAPC® plus probes unfold their full potential in combination with the APC 3 and the new VIO® 3n Fire electrosurgical generator, specifically dedicated to APC applications. The platform's architecture ensures seamless integration, fast recognition, and preconfigured APC mode settings tailored to the FiAPC® plus probe, resulting in enhanced workflow efficiency, precision, and user confidence.
Reliable performance in thermosensitive areas across specialties
While the FiAPC® plus probes are designed for a broad range of APC indications, their value becomes especially clear in procedures involving thermosensitive areas, whether in the gastrointestinal tract or the bronchial system. In areas such as the cecum, right colon, or narrow airways, where precision and limited thermal spread are essential, FiAPC® plus offers reliability and control through stable plasma ignition, reduced tissue sticking, and optimized energy delivery at the probe tip.
To support GI endoscopists and pulmonologists in applying APC, Erbe complements the launch of FiAPC® plus with a comprehensive offering of clinical education and training. This includes hands-on courses, structured learning modules, and on-site support through the Erbe Team: helping physicians navigate their APC journey from first use to expert application.
FiAPC® plus probes are now available in CE and CE-related markets. Additional markets will follow soon. With this latest development, Erbe reaffirms its commitment to pushing the boundaries of APC technology through user-centered innovation and clinical partnership.
To get into control visit the FiAPC plus website now.
[https://en.erbe-med.com/en-en/highlights/fiapc/]
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OR teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryo technology
An international network
- 20 international sales and service units
- 5 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- 2,100 employees worldwide
- Some 1,100 of them in Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714417615/en/
Contacts
Erbe Elektromedizin GmbH
Waldhoernlestrasse 17
72072 Tuebingen
erbe-med.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fen.erbe-med.co
m%2Fen-en%2Fhighlights%2Ffiapc%2F%3Fmtm_campaign%3DFiAPC%2520Plus%26mtm_source%3
DPR&esheet=54289214&newsitemid=20250714417615&lan=en-US&anchor=erbe-med.com&inde
x=3&md5=3252ee35fdab68ddca72c5b4f6160fbc
info@erbe-med.com
Contacts
David Malecki
Phone +49 7071 755-316
david.malecki@erbe-med.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom